7LMV

SPECIFIC INHIBITOR OF INTEGRIN ALPHA-V BETA-6


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.90 Å
  • R-Value Free: 0.268 
  • R-Value Work: 0.221 
  • R-Value Observed: 0.222 

wwPDB Validation   3D Report Full Report


This is version 1.2 of the entry. See complete history


Literature

De novo design of highly selective miniprotein inhibitors of integrins alpha v beta 6 and alpha v beta 8.

Roy, A.Shi, L.Chang, A.Dong, X.Fernandez, A.Kraft, J.C.Li, J.Le, V.Q.Winegar, R.V.Cherf, G.M.Slocum, D.Poulson, P.D.Casper, G.E.Vallecillo-Zuniga, M.L.Valdoz, J.C.Miranda, M.C.Bai, H.Kipnis, Y.Olshefsky, A.Priya, T.Carter, L.Ravichandran, R.Chow, C.M.Johnson, M.R.Cheng, S.Smith, M.Overed-Sayer, C.Finch, D.K.Lowe, D.Bera, A.K.Matute-Bello, G.Birkland, T.P.DiMaio, F.Raghu, G.Cochran, J.R.Stewart, L.J.Campbell, M.G.Van Ry, P.M.Springer, T.Baker, D.

(2023) Nat Commun 14: 5660-5660

  • DOI: https://doi.org/10.1038/s41467-023-41272-z
  • Primary Citation of Related Structures:  
    7LMV, 7LMX, 8TCF, 8TCG

  • PubMed Abstract: 

    The RGD (Arg-Gly-Asp)-binding integrins αvβ6 and αvβ8 are clinically validated cancer and fibrosis targets of considerable therapeutic importance. Compounds that can discriminate between homologous αvβ6 and αvβ8 and other RGD integrins, stabilize specific conformational states, and have high thermal stability could have considerable therapeutic utility. Existing small molecule and antibody inhibitors do not have all these properties, and hence new approaches are needed. Here we describe a generalized method for computationally designing RGD-containing miniproteins selective for a single RGD integrin heterodimer and conformational state. We design hyperstable, selective αvβ6 and αvβ8 inhibitors that bind with picomolar affinity. CryoEM structures of the designed inhibitor-integrin complexes are very close to the computational design models, and show that the inhibitors stabilize specific conformational states of the αvβ6 and the αvβ8 integrins. In a lung fibrosis mouse model, the αvβ6 inhibitor potently reduced fibrotic burden and improved overall lung mechanics, demonstrating the therapeutic potential of de novo designed integrin binding proteins with high selectivity.


  • Organizational Affiliation

    Department of Biochemistry and Institute for Protein Design, University of Washington, Seattle, WA, 98195, USA.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Integrin inhibitor
A, B, C, D, E
A, B, C, D, E, F, G, H, I, J, K, L
70synthetic constructMutation(s): 0 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
Sequence Annotations
Expand
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.90 Å
  • R-Value Free: 0.268 
  • R-Value Work: 0.221 
  • R-Value Observed: 0.222 
  • Space Group: P 31
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 92.27α = 90
b = 92.27β = 90
c = 82.42γ = 120
Software Package:
Software NamePurpose
PHENIXrefinement
XDSdata reduction
XDSdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Howard Hughes Medical Institute (HHMI)United States--

Revision History  (Full details and data files)

  • Version 1.0: 2022-08-10
    Type: Initial release
  • Version 1.1: 2024-02-21
    Changes: Data collection, Database references
  • Version 1.2: 2024-04-03
    Changes: Refinement description